🇺🇸 FDA

Intelligence · Clinical Pipeline

Neurology & CNS · Phase II

Neurology & CNS programs at Phase II — ClinicalTrials.gov pipeline intelligence.

Programs
230

Quick answer

Neurology & CNS Phase II programs: NovaPharmaNews indexes 230 matching clinical development programs from ClinicalTrials.gov with sponsor, modality, and NCT cross-links.

Top sponsors

Page 1 of 5

  1. 0.9% sodium chloride, GADOTERIC ACID

    Eli Lilly Co.

    Relapsing Multiple Sclerosis

    phase 2 small molecule active

    1 trial

  2. 00 mg/mL Concentrate for solution for infusion, VHB937

    Novartis Pharmaceuticals

    Alzheimer’s disease

    phase 2 small molecule active

    1 trial

  3. 18F-92

    The First People's Hospital of Lianyungang

    Alzheimer's Disease

    phase 2 small molecule active

    1 trial

  4. 18FMC225_FPG

    Fondazione Telethon ETS

    depression

    phase 2 small molecule active

    1 trial

  5. 5-(1-(2-[18F] fluoroethoxy))-[3-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-propyl]-5,6,7,8-tetrahydronaphthalen

    Disc Medicine

    Alzheimers Disease, sporadic Cerebral Amyloid Angiopathy, Parkinson

    phase 2 small molecule active

    1 trial

  6. A Multi-Center, Single Arm, Open-Label Extension Study to Evaluate the Long-term Safety and Efficacy of GSK4527226 [AL101] in Participants with Early Alzheimer’s Disease.

    GlaxoSmithKline

    Alzheimer's Disease

    phase 2 other active

    1 trial

  7. A Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy of Fenebrutinib in Relapsing Multiple Sclerosis

    Hoffmann-La Roche

    Relapsing Multiple Sclerosis

    phase 2 other active

    1 trial

  8. A phase 2 trial assessing Ifenprodil as a ReMyelinating repurpOsed Drug in Multiple Sclerosis – MODIF-MS

    Pari Pharma GmbH

    Multiple sclerosis

    phase 2 other active

    1 trial

  9. ABBV-552

    AbbVie

    Alzheimer's Disease (AD)

    phase 2 small molecule completed

    1 trial

  10. ACP-103

    Acadia Pharmaceuticals B.V.

    Schizophrenia

    phase 2 small molecule completed

    1 trial

  11. ACP-104

    Acadia Pharmaceuticals B.V.

    Schizophrenia

    phase 2 small molecule completed

    2 trials

  12. ACT-1004-1239 matching placebo

    Lacuna Pharma Pty Ltd

    Progressive multiple sclerosis (MS)

    phase 2 small molecule active

    1 trial

  13. ADX48621

    Addex Therapeutics

    Parkinson's Disease

    phase 2 small molecule completed

    1 trial

  14. ALECTINIB

    Hoffmann-La Roche

    ALK fusion-positive extracranial solid or primary CNS tumors who have progressed following prior treatment or who have no satisfactory treatment available

    phase 2 small molecule active

    1 trial

  15. AMBROXOL , Microcrystalline cellulose

    Disc Medicine

    Parkinson's disease

    phase 2 small molecule active

    1 trial

  16. AMX0035

    Amylyx Pharmaceuticals EMEA B.V.

    Alzheimer Disease

    phase 2 small molecule completed

    1 trial

  17. ARICEPT 10mg comprimidos recubiertos con película

    The George Institute

    Parkinson's disease

    phase 2 small molecule active

    1 trial

  18. ARO-MAPT-SC

    Arrowhead Pharmaceuticals Ireland Limited

    Alzheimer Disease

    phase 2 small molecule active

    1 trial

  19. ATA188

    Evidence Based Cataract Study Group

    Primary Progressive Multiple Sclerosis

    phase 2 mab terminated

    1 trial

  20. AV-101

    Vistagen Therapeutics

    Parkinson Disease

    phase 2 small molecule active

    1 trial

  21. AXS-05

    Axsome Therapeutics

    Treatment Resistant Depression

    phase 2 small molecule completed

    1 trial

  22. AXS-05 (dextromethorphan-bupropion)

    Axsome Therapeutics

    Treatment Resistant Depression

    phase 2 small molecule terminated

    1 trial

  23. Active Treatment- CT1812 100 mg

    COGNITION THERAPEUTICS INC

    Alzheimer Disease

    phase 2 small molecule completed

    1 trial

  24. Active drug: pimavanserin 17mg (2 strength tablets)

    Acadia Pharmaceuticals B.V.

    Parkinson Disease

    phase 2 small molecule completed

    1 trial

  25. Amiloride

    United Therapeutics Europe Ltd

    Secondary Progressive Multiple Sclerosis

    phase 2 small molecule completed

    1 trial

  26. Amyvid 1900 MBq/mL solution for injection, Neuraceq 300 MBq/mL solution for injection, 0.9% (w/v) sodium chloride (Normal Saline), VIZAMYL 400 MBq/mL solution for injection, Amyvid 800 MBq/mL solution for injection

    GlaxoSmithKline

    Alzheimer's Disease

    phase 2 small molecule active

    1 trial

  27. Amyvid 800 MBq/mL solution for injection, ACU193 matching Placebo, Neuraceq 300 MBq/mL solution for injection, ACU193, VIZAMYL 400 MBq/mL solution for injection

    Acumen Pharmaceuticals

    Early Alzheimer’s Disease (Mild Cognitive Impairment and Mild Dementia Due to Alzheimer’s Disease)

    phase 2 small molecule active

    1 trial

  28. Aplindore

    LIGAND PHARMACEUTICALS INC

    Early Stage Parkinson's Disease

    phase 2 small molecule completed

    1 trial

  29. Armodafinil

    Teva Pharma GmbH

    Bipolar I Depression

    phase 2 small molecule completed

    1 trial

  30. Atomoxetin STADA 40 mg Hartkapseln, GELATIN

    Pari Pharma GmbH

    Healthy subjects with no neurological or psychiatric disorders

    phase 2 small molecule active

    1 trial

  31. Azeliragon

    vTv Therapeutics

    Alzheimer Disease

    phase 2 small molecule terminated

    1 trial

  32. B-CIT and SPECT imaging

    United Therapeutics Europe Ltd

    Parkinson Disease

    phase 2 small molecule completed

    1 trial

  33. BHV-7000, BHV-7000

    Biohaven Bioscience Ireland Limited

    Refractory Focal Onset Epilepsy

    phase 2 small molecule active

    1 trial

  34. BHV-7000, BHV-7000, Placebo for BHV-7000

    Biohaven Bioscience Ireland Limited

    Refractory Focal Onset Epilepsy

    phase 2 small molecule active

    1 trial

  35. BIIB122 225 mg

    Denali Therapeutics

    Parkinson Disease

    phase 2 small molecule active

    1 trial

  36. BIIB122, Placebo to BIIB122

    Denali Therapeutics

    Parkinson’s disease

    phase 2 small molecule active

    1 trial

  37. BMB-101

    BRIGHT MINDS BIOSCIENCES INC.

    Absence Epilepsy

    phase 2 small molecule active

    1 trial

  38. Bepranemab, Placebo matching and without active substance, Neuraceq 300 MBq/mL solution for injection, (18F) GTP1

    Lacuna Pharma Pty Ltd

    Alzheimer’s Disease

    phase 2 small molecule active

    1 trial

  39. Berubicin hydrochloride

    Rani Therapeutics Holdings

    central nervous system (CNS) lymphomas

    phase 2 small molecule active

    1 trial

  40. Bone marrow mesenchymal stem cells autologous

    Lxo Ireland Designated Activity Company

    Multiple Sclerosis

    phase 2 other completed

    1 trial

  41. Bupropion

    BRIGHT MINDS BIOSCIENCES INC.

    Schizophrenia and Disorders With Psychotic Features

    phase 2 small molecule completed

    1 trial

  42. CC-97489, CC-97489, CC-97489 1mg , CC-97489 3mg

    Celgene Europe Limited

    Multiple Sclerosis Spasticity

    phase 2 small molecule active

    1 trial

  43. CERE-110: Adeno-Associated Virus injection Surgery

    SANGAMO THERAPEUTICS, INC

    Alzheimer's Disease

    phase 2 small molecule completed

    1 trial

  44. CERE-120 (Adeno-Associated Virus Serotype 2 [AAV2]-Neurturin [NTN])

    SANGAMO THERAPEUTICS, INC

    Idiopathic Parkinson's Disease

    phase 2 small molecule completed

    1 trial

  45. CERE-120: Adeno-Associated Virus Delivery of Neurturin

    SANGAMO THERAPEUTICS, INC

    Idiopathic Parkinson's Disease

    phase 2 mab completed

    1 trial

  46. CET/PT

    BRIGHT MINDS BIOSCIENCES INC.

    Schizophrenia

    phase 2 other completed

    1 trial

  47. CNSA-001

    PTC THERAPEUTICS, INC.

    Gastroparesis

    phase 2 small molecule completed

    1 trial

  48. CT1812

    COGNITION THERAPEUTICS INC

    Alzheimer's Disease

    phase 2 small molecule completed

    1 trial

Frequently asked questions

How many neurology & cns Phase II programs exist?

230 programs match both the therapeutic area and stage filters in our published index.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.